Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized
in cognitively unimpaired (CU) elderly individuals. We therefore tested if plasma …

Objective We examined whether plasma β-amyloid (Aβ) 42/Aβ40, as measured by a high-
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …

Importance Amyloid positron emission tomography (PET) detects amyloid plaques in the
brain, a core neuropathological feature of Alzheimer disease. Objective To determine if …

Importance Accurate blood-based biomarkers for Alzheimer disease (AD) might improve the
diagnostic accuracy in primary care, referrals to memory clinics, and screenings for AD trials …

Importance Existing cerebrospinal fluid (CSF) or imaging (tau positron emission
tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers …

Objective: To test whether plasma tau is altered in Alzheimer disease (AD) and whether it is
related to changes in cognition, CSF biomarkers of AD pathology (including β-amyloid [Aβ] …

Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD)
and to understand the drug development process for new AD therapies. Methods We …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …